Dechra Pharmaceuticals Dividends - DPH

Dechra Pharmaceuticals Dividends - DPH

Buy
Sell
Best deals to access real time data!
Silver
Monthly Subscription
for only
£17.37
Level 2 Basic
Monthly Subscription
for only
£62.08
UK/US Silver
Monthly Subscription
for only
£30.59
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Dechra Pharmaceuticals Plc DPH London Ordinary Share GB0009633180 ORD 1P
  Price Change Price Change % Stock Price Last Trade
-18.00 -0.51% 3,492.00 16:35:15
Close Price Low Price High Price Open Price Previous Close
3,492.00 3,470.00 3,526.00 3,486.00 3,510.00
more quote information »
Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Dechra Pharmaceuticals DPH Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount
07/09/2020FinalGBX2430/06/201930/06/202005/11/202006/11/202027/11/202034.29
24/02/2020InterimGBX10.2930/06/201930/06/202005/03/202006/03/202008/04/20200
02/09/2019FinalGBX22.130/06/201830/06/201924/10/201925/10/201915/11/201931.6
25/02/2019InterimGBX9.530/06/201830/06/201907/03/201908/03/201908/04/20190
03/09/2018FinalGBX18.1730/06/201730/06/201825/10/201826/10/201816/11/201825.5
26/02/2018InterimGBX7.3330/06/201730/06/201808/03/201809/03/201806/04/20180
04/09/2017FinalGBX15.3330/06/201630/06/201726/10/201727/10/201717/11/201721.44
27/02/2017InterimGBX6.1130/06/201630/06/201709/03/201710/03/201707/04/20170
05/09/2016FinalGBX12.9130/06/201530/06/201627/10/201628/10/201618/11/201618.46
22/02/2016InterimGBX5.5530/06/201530/06/201610/03/201611/03/201606/04/20160
07/09/2015FinalGBX11.8230/06/201430/06/201529/10/201530/10/201520/11/201516.94
23/02/2015InterimGBX5.1230/06/201430/06/201512/03/201513/03/201507/04/20150
08/09/2014FinalGBX10.6530/06/201330/06/201406/11/201407/11/201421/11/201415.4
25/02/2014InterimGBX4.7530/06/201330/06/201412/03/201414/03/201408/04/20140
03/09/2013FinalGBX9.6630/06/201230/06/201306/11/201308/11/201322/11/201314
26/02/2013InterimGBX4.3430/06/201230/06/201313/03/201315/03/201309/04/20130
04/09/2012FinalGBX8.530/06/201130/06/201207/11/201209/11/201223/11/201212.6
21/02/2012InterimGBX4.130/06/201130/06/201207/03/201209/03/201210/04/20120
06/09/2011FinalGBX8.430/06/201030/06/201109/11/201111/11/201125/11/201112.1
22/02/2011InterimGBX3.730/06/201030/06/201109/03/201111/03/201107/04/20110
07/09/2010FinalGBX7.230/06/200930/06/201010/11/201012/11/201010/12/201010.5
23/02/2010InterimGBX3.330/06/200930/06/201003/03/201005/03/201001/04/20100
01/09/2009FinalGBX6.130/06/200830/06/200911/11/200913/11/200911/12/20099.1
02/09/2008FinalGBX2.7530/06/200730/06/200812/11/200814/11/200812/12/20080
25/02/2007InterimGBX2.501/07/200631/12/200607/03/200709/03/200710/04/20070
05/09/2006FinalGBX4.3330/06/200530/06/200625/10/200627/10/200624/11/20066.24
28/02/2006InterimGBX1.9101/07/200531/12/200508/03/200610/03/200607/04/20060
06/09/2005FinalGBX3.530/06/200430/06/200526/10/200528/10/200525/11/20055.2
01/03/2005InterimGBX1.701/07/200431/12/200409/03/200511/03/200507/04/20050
07/09/2004FinalGBX3.1530/06/200330/06/200427/10/200429/10/200424/11/20044.7
02/03/2004InterimGBX1.5501/07/200331/12/200310/03/200412/03/200407/04/20040
02/09/2003FinalGBX2.7530/06/200230/06/200329/10/200331/10/200326/11/20034.12
04/03/2003InterimGBX1.3701/07/200231/12/200212/03/200314/03/200309/04/20030
03/09/2002FinalGBX2.7530/06/200130/06/200229/10/200201/11/200227/11/20024.12
26/02/2002InterimGBX1.3701/07/200131/12/200106/03/200208/03/200208/04/20020
04/09/2001FinalGBX2.530/06/200030/06/200131/10/200102/11/200128/11/20013.75
28/02/2001InterimGBX1.2501/07/200031/12/200007/03/200109/03/200104/04/20010

Top Dividend Posts

DateSubject
07/9/2020
06:56
steeplejack: The interim dividend was up 8.3% so the final dividend has been increased by a similar amount.The earnings figures are modestly ie about 2% better than consensus,broadly in line.
07/9/2020
06:50
lasata: Was the increased dividend expected?
07/9/2020
06:34
lasata: Ok results...nothing special. Good to see dividend is up
15/9/2019
11:46
sarkasm: Https://www.marketscreener.com/DECHRA-PHARMACEUTICALS-4003059/?type_recherche=rapide&mots=DPH Summary The company has poor fundamentals for a short-term investment strategy. Strengths Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock. Over the past year, analysts have regularly revised upwards their sales forecast for the company. Analysts covering this company mostly recommend stock overweighting or purchase. Within the weekly time frame the stock shows a bullish technical configuration above the support level at 2478 GBp Weaknesses Stock prices approach a strong long-term resistance in weekly data at GBp 3036. Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity. Based on current prices, the company has particularly high valuation levels. The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 90.41 times its estimated earnings per share for the ongoing year. The firm pays small or no dividend to shareholders. For that reason, it is not a yield company. For the past seven days, analysts have been lowering their EPS expectations for the company. For the last few months, analysts have been revising downwards their earnings forecast.
15/9/2019
11:44
sarkasm: MIDAS SHARE TIPS UPDATE: Drugs for pets firm Dechra Pharmaceuticals booms By Joanne Hart for The Mail on Sunday Published: 11:30 BST, 15 September 2019 | Updated: 11:30 BST, 15 September 2019 e-mail View comments Dogs have always played an important role in Korean life. Once, they were a feature on restaurant menus. Today, they are more often seen at the end of a lead. The shift is part of a broader trend across emerging markets, as pet ownership becomes something of a status symbol among aspiring consumers. The more people own cats and dogs, the more they spend on looking after them, to the benefit of Dechra Pharmaceuticals, which makes and sells drugs for pets and other animals. The more people own cats and dogs, the more they spend on looking after them, to the benefit of Dechra Pharmaceuticals, which makes and sells drugs for pets and other animals +1 Drugs business: The more people own cats and dogs, the more they spend on looking after them Midas originally recommended the stock in 2008, when it was £3.97. We recommended it again in 2015, by which time the price had surged to £9.85. Last Friday, the shares closed at £28.90, having almost tripled in the past four years alone. Looking ahead, long-standing chief executive Ian Page is optimistic and recent figures suggest he has good reason to be. RELATED ARTICLES Previous 1 Next MIDAS SHARE TIPS: Here's a VERY hot tip - Filta fryer... MIDAS SHARE TIPS: Want a rock solid shelter? This new... Share this article Share HOW THIS IS MONEY CAN HELP How to choose the best (and cheapest) DIY investing Isa - and our pick of the platforms Dechra Pharmaceuticals: Latest price and charts Annual results to June 30, released earlier this month, showed a 17.5 per cent increase in revenues to £482 million, a 27 per cent rise in underlying profits to £127 million and a 24 per cent hike in the dividend to 31.6p. The company’s performance is all the more impressive, as many peers have struggled recently, and Dechra itself has had to cope with increasingly stringent regulation and potential issues around a No Deal Brexit. Free investing guides The group’s resilience derives largely from a simple but effective strategy: listening to what vets need and creating products that satisfy those needs, particularly in specialist areas. Dechra’s best-selling drug, for example, is Vetoryl, used to treat dogs with Cushing’s disease, a hormonal disorder. Initially, Dechra operated only in the UK. Today, it sells to vets around the world. Just over 70 per cent of sales relate to pets, but the group generates strong growth from farm animal and horse products too. Dechra manufactures half the drugs that it sells and buys the rest from third-party producers. Over time, Page would like to make more drugs in-house and the company has a strong pipeline, including a diabetes treatment for cats and dogs that can be injected weekly instead of daily – a clear bonus for pets and their owners. Growth is also likely to come from more geographic expansion and well-chosen acquisitions, as Page has bought several businesses over the years and successfully integrated them into the business. Brokers forecast a continued increase in sales, profits and dividends next year and beyond. MIDAS VERDICT Dechra has come a long way since chief executive Ian Page took the helm in 2001, enjoying 17 years of consistent, double-digit earnings growth. Investors who bought in 2008 – and later in 2015 – have done well and may choose to bank some profits. But most analysts believe the stock could hit £33 in the next year or two so shareholders should retain most of their stock.
06/9/2018
09:53
gbh2: It's a poor dividend when compared to GSK.
06/9/2018
09:12
steeplejack: I think the Times article very sound but they've used the "reported" eps calculation to arrive at a 71 PER.The more widely utilised figure is below.The shares are on a historic PE of around 30,still high but not crazy high.I sold out higher up after the figures but if they come back under £20,I'll consider getting back in. Strong financial performance: * Revenue growth of 13.9% to GBP407.1 million. * Underlying operating profit growth of 24.0% to GBP99.2 million. * Underlying EBIT margin expansion of 200 bps to 24.4%. * Underlying diluted EPS increased by 20.9% to 76.45 pence. * Full year dividend of 25.50 pence.
04/9/2018
19:40
wetdream: It shouldn’t happen to a vet supplier The Times4 September 2018Miles Costello Tempus dechra pharmaceuticals STEVEN G SMITH/EYEEM/GETTY IMAGES Shares in Dechra lost more than a fifth of their value yesterday after the maker of veterinary drugs said that it had embarked on preparations for a no-deal Brexit. Dechra said that it would be setting up a laboratory inside the eurozone to ensure its products met European Union guidelines if Britain quit without a mutual agreement on testing and drug approvals. It said that the cost, at about £1.2 million, would be immaterial, but shareholders took fright at the potential fallout for Dechra once Britain is no longer a member of the bloc. The shares closed 668p lower, or 21.4 per cent, at £24.52. Dechra Pharmaceuticals suffered the sharpest ever one-day fall in its share price yesterday as investors took fright at an array of risks ranging from a hard Brexit to the changing face of the veterinary market. It’s hard not to conclude that the drop, of more than 20 per cent, was overdone. There are many moving parts at Dechra, a supplier of products to veterinary practices across Europe and North America, but none appear to merit a fall such as that. Dechra Pharmaceuticals traces its history back to 1819 when it was founded as Arnolds & Son, a business that made prosthetic limbs. Having moved into the veterinary market during the Crimean war, it has expanded through acquisitions and organic growth and now specialises in treatments such as vaccines and antibiotic sprays for pets, horses and “food-producing animals”, such as chickens and pigs, and produces specialist diet foods for animals. It operates in 50 countries, mainly in Europe and North America. Dechra operates in a consolidating market. Veterinary practices are merging, mainly to create benefits of scale, at the fastest rate ever (especially in Britain). At the same time, suppliers, which it uses to get its products to vets, increasingly are concentrating on prioritising their discounted own-brand products. Distributors, particularly in North America, also are merging. Dechra has been happy to get involved in this M&A activity. In the past 12 months it’s bought Rxvet, a pet products business in New Zealand, AST Farma, which also makes treatments for dogs and cats and the like in the Netherlands, and Le Vet, which operates in non-Dutch markets in the European Union. Enlarged veterinary practices — and, indeed, bigger distributors — will have much more muscle in negotiating discounts for buying or selling on Dechra’s products in bulk. In practice, though, Dechra can live with this as it will be far cheaper to service a single big customer where before it may have been dealing with 25 or even 50 separate companies. Then there’s Brexit. Dechra told its investors yesterday that it was implementing a plan based on a nodeal departure from the EU next March, under which the bloc would refuse to recognise products tested and authorised in Britain. Dechra is setting up an EU-based company so that there will be no technical barrier to trade. In addition, it is setting up a laboratory in the bloc, equipped with staff who can test products to ensure that they conform with EU guidelines if it turns out that they are required separately. This is a headache, but will cost Dechra only £200,000 up front, plus a one-off expense of £1 million and additional operating costs of £800,000 a year — peanuts for a business with annual revenues of more than £400 million and a profit margin of 24.4 per cent. In short, none of this justifies the slump in its price; Dechra ended the day yesterday down 668p, or 21.4 per cent, at £24.52. Its annual numbers were strong. Taking into account the contribution from acquisitions, there was doubledigit growth in both profits and revenues over the 12 months to the end of June. The United States, where there were no deals last year, increased its revenues by a healthy 18.2 per cent and the profitability of the consolidated businesses in Europe improved sharply. Nevertheless Dechra shares are insanely highly rated, even after yesterday, trading on an earnings multiple of a whopping 71 times and with a dividend yield just shy of 1 per cent. The group is in good shape and seems well placed to adapt to its changing market; still, it’s as hard to justify buying the shares as it is to defend yesterday’s fall.
03/9/2018
09:50
steeplejack: (Sharecast News) - Veterinary pharmaceutical business Dechra Pharmaceuticals issued a solid set of preliminary results on Monday, but this was enough to satisfy investors as the shares were sent tumbling. The FTSE 250 firm reported revenue growth of 13.9% to £407.1m for the year ended 30 June, with underlying operating profit growing 24.0% to £99.2m as underlying EBIT margins expanded 200 basis points to 24.4%.Underlying diluted earnings per share were ahead 20.9% to 76.45p.The Dechra board declared a full-year dividend of 25.5p.On the operational front, Dechra highlighted the acquisition of AST Farma and Le Vet in the Netherlands and the European Union, and RxVet in New Zealand.It said it outperformed in the majority of its countries and therapeutic sectors, while making "several" new global product registrations, with new opportunities secured."Dechra has delivered another successful year from both a financial and strategic perspective," said chief executive officer Ian Page.Dechra shares, having scampered up more than five-fold in the last six years, fell 15% to 2,650p, taking them back to where they were around six months ago.It was a "mixed update" said Russ Mould, investment director at broker AJ Bell, that showed "the dangers of a high valuation colliding with less than positive news" after a the strong dynamics behind the animal drug market helped underpin a multi-year advance in its shares."On the face of it, Dechra's full year results still look good with underlying profit, excluding the impact of accounting adjustments on some acquisitions, up more than 20%," he said."What may be concerning the market are references to contingency plans for a 'hard Brexit' and the fact an increasing number of distributors are focusing on the sale and marketing of their own products. These factors could prevent the company churning out the same stellar numbers as it has done historically."
26/2/2018
08:37
steeplejack: Although signalled at the update stage a month or so back,these figures confirm an excellent performance with margin improvement and solid cash flow.The dividend is up 20%.OutlookDechra has performed well in the Period with solid revenue growth in EU pharmaceuticals and strong revenue growth in NA Pharmaceuticals from the existing business. This has been delivered through the consistent application of our successful strategy, converting pipeline opportunities, leveraging our strong portfolio, and expanding our geographic presence. The acquisitions of AST Farma, Le Vet and RxVet will supplement our opportunities further.Current trading continues in line with management expectations and the initial phase of integration of the AST Farma/Le Vet acquisition is progressing well. The Board remains confident that we can continue to implement our strategy and meet our expectations for the current financial year, and deliver further growth in the future.
ADVFN Advertorial
Your Recent History
LSE
DPH
Dechra Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201031 19:30:54